Researchers pinpoint a cellular process called 'clonal hematopoiesis' as a new risk factor for cardiovascular problems. In ...

Achilles Therapeutics has announced it will discontinue its tumor-infiltrating lymphocyte (TIL)-based clonal neoantigen T ...

A new study has settled a prolonged dispute within the medical community by showing that mutations associated with clonal ...

A type of zooplankton, Daphnia pulex (a.k.a. the water flea) is a microscopic crustacean whose unique reproduction habits ...

Antibiotics are a lifesaving tool. Yet, due to their chronic overuse, microbes are evolving and developing immunity against ...

Achilles to discontinue development of TIL-based cNeT therapy––Cash position of $95.1 million as of June 30, 2024––BofA Securities engaged to ...

Researchers at Saint Louis University School of Medicine investigated differences in T-cell responses between male and female ...

Shares of Achilles Therapeutics plc (NASDAQ:ACHL) surged Thursday after the biotechnology firm revealed plans to discontinue ...

The Hematology Laboratory, Molecular Hematology Unit, at Sheba Medical Center, Israel's largest medical center, is conducting ...

The firm is discontinuing its CHIRON and THETIS trials after lackluster data and is planning for potential third-party deals and workforce layoffs.

(Alliance News) - Syncona Ltd on Thursday announced that Achilles Therapeutics will discontinue its lead TIL-based cNeT program, close its Phase I/IIa CHIRON and THETIS clinical trials and explore ...